BIM
NBIX icon

Bogle Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

Bogle Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-32,165
Closed -$3.92M – 284
2020
Q2 		$3.92M Buy
+32,165
New +$3.55M 0.65% 63
2013
Q3 		– Sell
-81,193
Closed -$1.09M – 334
2013
Q2 		$1.09M Buy
+81,193
New +$997K 0.13% 198

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bogle Investment Management's NBIX Position: Q3 2020 in Review

Bogle Investment Management sold out of Neurocrine Biosciences (NBIX) in Q3 2020, closing a stake of 32,165 shares — an estimated $3.92M sold.

Bogle Investment Management first reported a position in NBIX in Q2 2013 and held it in 2 quarters. The position peaked at $3.92M in Q2 2020. 419 funds tracked by Wall St. Rank hold NBIX as of Q3 2020.

  • Bogle Investment Management reported no remaining Neurocrine Biosciences position as of Q3 2020 after selling out during the quarter.
  • Bogle Investment Management sold 32,165 Neurocrine Biosciences shares in Q3 2020, an estimated $3.92M.
  • Bogle Investment Management first reported a position in Neurocrine Biosciences in Q2 2013 and held it in 2 quarters.
  • Bogle Investment Management's Neurocrine Biosciences position peaked at $3.92M in Q2 2020.
  • 419 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2020.

Based on Bogle Investment Management's 13F filing for Q3 2020, filed 12 Nov 2020.